UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | June 18, 2009 |
Anadys Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 000-50632 | 22-3193172 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3115 Merryfield Row, San Diego, California | | 92121 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | (858) 530-3600 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On June 18, 2009, Anadys Pharmaceuticals, Inc. (the "Company") entered into a Sublease Agreement (the "Lease") with Phenomix Corporation for the lease of approximately 13,893 square feet of office and laboratory space in which the Company will conduct its ongoing operations. Each month during the approximate 19.5 month term of the Lease commencing on or about July 15, 2009, the Company is required to remit base rent of $29,869.95. The Lease also provides for additional payments, including a $29,869.95 security deposit, common area maintenance charges,
taxes, maintenance and utilities. The newly leased space, located in San Diego, California, will replace the Company's current headquarters and research and development facility in which the Company is occupying approximately 40,000 square feet under a lease expiring on August 1, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Anadys Pharmaceuticals, Inc. |
| | | | | |
| June 24, 2009 | | By: | | /s/ James T. Glover
|
| | | | |
|
| | | | | Name: James T. Glover |
| | | | | Title: Senior Vice President, Operations and Chief Financial Officer |
